aTyr Pharma to Present at March Investor Conferences

Rhea-AI Summary

aTyr Pharma (Nasdaq: LIFE), a biotherapeutics company, announced its participation in two investor conferences in March 2023. The first event is the 35th Annual Roth Conference on March 14, 2023, at 10:00 am PDT in Dana Point, CA, featuring a fireside chat. The second is the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 10:00 am EDT, which will be held virtually as a corporate presentation.

Management will also engage in one-on-one investor meetings. A replay of the corporate presentation will be available on aTyr’s investor website.

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present at two upcoming investor conferences scheduled to take place in March 2023.

Details of the presentations appear below:

Conference: 35^th Annual Roth Conference
Date: Tuesday, March 14, 2023
Time: 10:00am PDT
Location: Dana Point, CA
Format: Fireside Chat

Conference: Oppenheimer 33^rd Annual Healthcare Conference
Date: Wednesday, March 15, 2023
Time: 10:00am EDT
Location: Virtual
Format: Corporate Presentation

In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. A webcast and replay of the Corporate Presentation will be available on the Investor’s section of the company’s website at www.atyrpharma.com. For more information, please contact investorrelations@atyrpharma.com.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com

FAQ

What events is aTyr Pharma attending in March 2023?

aTyr Pharma will present at the 35th Annual Roth Conference on March 14 and the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023.

What time is aTyr Pharma's presentation at the Roth Conference?

The presentation at the Roth Conference is scheduled for 10:00 am PDT on March 14, 2023.

How can I access the replay of aTyr Pharma's corporate presentation?

The replay of aTyr Pharma's corporate presentation will be available on their investor website after the event.

Where will the Oppenheimer Healthcare Conference be held?

The Oppenheimer 33rd Annual Healthcare Conference will be held virtually on March 15, 2023.

What is aTyr Pharma's primary focus in research and development?

aTyr Pharma focuses on developing medicines from its tRNA synthetase platform, particularly the clinical candidate efzofitimod for fibrotic lung disease.